Literature DB >> 28577830

Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?

Shankar Siva1, Ben J Slotman2.   

Abstract

This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2017        PMID： 28577830     DOI： 10.1016/j.semradonc.2017.03.003

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN： 1053-4296            Impact factor:   5.934


  7 in total

1.  Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.

Authors:  Heather M McGee; Megan E Daly; Sohelia Azghadi; Susan L Stewart; Leslie Oesterich; Jeffrey Schlom; Renee Donahue; Jonathan D Schoenfeld; Qian Chen; Shyam Rao; Ruben C Fragoso; Richard K Valicenti; Robert J Canter; Emmanual M Maverakis; William J Murphy; Karen Kelly; Arta M Monjazeb
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-04-22       Impact factor: 7.038

2.  Pulmonary metastasectomy: a cross sectional survey.

Authors:  James M Caristo; David H Tian; Tristan D Yan
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose.

Authors:  Kamran A Ahmed; Jacob G Scott; John A Arrington; Arash O Naghavi; G Daniel Grass; Bradford A Perez; Jimmy J Caudell; Anders E Berglund; Eric A Welsh; Steven A Eschrich; Thomas J Dilling; Javier F Torres-Roca
Journal:  J Thorac Oncol       Date:  2018-05-05       Impact factor: 20.121

4.  Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases.

Authors:  Patrick Berkovic; Akos Gulyban; Gilles Defraene; Laurie Swenen; David Dechambre; Paul Viet Nguyen; Nicolas Jansen; Carole Mievis; Pierre Lovinfosse; Levente Janvary; Maarten Lambrecht; Gert De Meerleer
Journal:  BMC Cancer       Date:  2020-05-08       Impact factor: 4.430

5.  Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes.

Authors:  Rosie Cooke; Philip Camilleri; Kwun-Ye Chu; Séan M O'Cathail; Maxwell Robinson; Frank Van Den Heuvel; Maria A Hawkins
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2020-02-17

6.  Lung stereotactic body radiation therapy: personalized PTV margins according to tumor location and number of four-dimensional CT scans.

Authors:  Pierre Trémolières; Ana Gonzalez-Moya; Amaury Paumier; Martine Mege; Julien Blanchecotte; Christelle Theotime; Damien Autret; Stéphane Dufreneix
Journal:  Radiat Oncol       Date:  2022-01-10       Impact factor: 3.481

Review 7.  Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done.

Authors:  Austin J Bartl; Mary Mahoney; Mark W Hennon; Sai Yendamuri; Gregory M M Videtic; Kevin L Stephans; Shankar Siva; Mark K Farrugia; Sung Jun Ma; Anurag K Singh
Journal:  Cancers (Basel)       Date:  2022-02-03       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.